BioSpectrum ASIA EDITION
the business of Bio & Health Sciences

IMG Pharma enters into definitive agreement to acquire Matsumoto Pharmaceutical in Japan

April 27, 2026 | News

To support the development of a scalable pharmaceutical and health product platform

IMG Pharmaceutical Co, a majority-owned subsidiary of IMG Japan, the Group's holding company, has entered into a definitive agreement to acquire Matsumoto Pharmaceutical Co, a Japanese pharmaceutical manufacturer.

IMG Medical Group operates an integrated healthcare platform across Asia, providing structured clinical services and long-term health management across the full lifecycle of care—from life creation and optimisation to preservation. Within this framework, IMG Pharma serves as the Group's pharmaceutical and product platform, translating clinical needs and medical pathways into standardised, scalable pharmaceutical and health products.

Founded in 1948, Matsumoto Pharmaceutical has established a mature OTC product system, with more than 50 registered drug approvals across Class 1, 2, and 3 categories and over 30 trademarks. Its product portfolio spans digestive, respiratory, and dermatological areas, as well as metabolic and physiological function-related segments.

Matsumoto Pharmaceutical currently operates two pharmaceutical manufacturing facilities in the Kansai region, with a combined site area exceeding 10,000 square meters, supporting its established production and OTC manufacturing capabilities.

IMG Pharma operates with Kobe as its core R&D and industrialisation hub, leveraging the Kobe Biomedical Innovation Cluster (KBIC), one of Japan's leading life science ecosystems. The dompany is advancing research and product development across regenerative and bioactive domains, including DPSC (dental pulp stem cell-related pathways), iPS cell-related technologies, placenta-derived bioactive components, and NAD-related compounds, with a focus on translational development and productisation.

This integration combines IMG Pharma's biopharmaceutical and translational capabilities with Matsumoto Pharmaceutical's manufacturing foundation and OTC product system, forming a multi-layered product capability structure. It is expected to support the development of a scalable pharmaceutical and health product platform addressing long-term health management needs.